TEAD Inhibitors Sensitize KRAS^G12C Inhibitors via Dual Cell Cycle Arrest in KRAS^G12C-Mutant NSCLC

KRAS^G12C is one of the most common mutations detected in non-small cell lung cancer (NSCLC) patients, and it is a marker of poor prognosis. The first FDA-approved KRAS^G12C inhibitors, sotorasib and adagrasib, have been an enormous breakthrough for patients with KRAS<sup>G12C</s...

Полное описание

Библиографические подробности

Главные авторы:	Salvina Laura Tammaccaro, Philippe Prigent, Jean-Christophe Le Bail, Odette Dos-Santos, Laurent Dassencourt, Myriam Eskandar, Armelle Buzy, Olivier Venier, Jean-Claude Guillemot, Yaligara Veeranagouda, Michel Didier, Emmanuel Spanakis, Tokuwa Kanno, Matteo Cesaroni, Stephane Mathieu, Luc Canard, Alhassan Casse, Fanny Windenberger, Loreley Calvet, Laurence Noblet, Sukhvinder Sidhu, Laurent Debussche, Jurgen Moll, Iris Valtingojer
Формат:	Artigo
Язык:	Inglês
Опубликовано:	MDPI AG 2023-04-01
Серии:	Pharmaceuticals
Предметы:	YAP1-TEAD resistance KRAS<sup>G12C</sup> NSCLC cell cycle arrest
Online-ссылка:	https://www.mdpi.com/1424-8247/16/4/553
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!